Genzyme Molecular Oncology begins Phase I/II trial

GZMO began a U.S, Phase I/II trial of its in vivo melanoma gene therapy vaccine in 36 patients with Stage II, III or IV melanoma who have been surgically resected. The vaccine employs an adenovirus ve...